Rigel Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

LEASES (Tables)

6 Months Ended

Jun. 30, 2023

The components of our operating lease expense were as follows (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2023		2022		2023		2022
Fixed operating lease expense	$	166	$	1,340	$	778	$	2,680
Variable operating lease expense (net credit)		(42)		125		30		391
Total operating lease expense	$	124	$	1,465	$	808	$	3,071

Supplemental information related to our operating lease were as follow (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2023		2022		2023		2022
Cash payments included in the measurement of operating lease liabilities	$	178	$	2,630	$	1,174	$	5,226

Supplemental information related to our operating sublease was as follow (in thousands):

The following table presents the future lease payments as of June 30, 2023 (in thousands):


Remainder of 2023	$	360
2024		739
2025		301
Total minimum payments required	$	1,400